期刊文献+

ImmunoCyt和尿脱落细胞学检查对膀胱移行细胞癌的早期诊断价值

ImmunoCyt for the Early Diagnosis of Bladder Transitional Cell Cancer (a Report of 138 Cases)
下载PDF
导出
摘要 【目的】探讨ImmunoCyt检查在膀胱移行细胞癌早期诊断和随访中的作用。【方法】2006年9月至2008年3月对可疑膀胱癌患者138例,其中25例经尿道膀胱肿瘤电切术后的随访者,113例有肉眼或镜下血尿患者,分别进行尿脱落细胞学和ImmunoCyt检查。所有病人均行膀胱镜检查,对可疑组织活检。【结果】膀胱镜检和病理证实34例为膀胱移行细胞癌。ImmunoCyt敏感性为88.2%,与尿脱落细胞学检查(47.1%)相比差异有显著性意义(PdO.05)。两种检查方法相结合的敏感性为91.2%。ImmunoCyt和尿脱落细胞学的特异性分别为80.4%和95.3%。【结论】早期检出膀胱癌ImmunoCyt较尿细胞学更敏感,二者结合使用可在保持高特异性的同时提高敏感性,适合大规模可疑人群的普查及复发可能性较小的低级、低期膀胱癌的术后随访。 [Objective] To study the role of ImmunoCyt test in the early diagnosis and follow-up of bladder transitional cell cancer. [Methods] A total of 138 suspected patients with bladder cancer were included. Among them 25 cases had undergone transurethral resection of superficial transitional cell carcinoma and had been followed up for at least 3 months. The other 113 cases had hematuria. All the patients were evaluated with both standard cytology and ImmunoCyt test. Then all of them underwent cystoscopy and suspected lesions underwent biopsy. [Results] Twenty eight cases were confirmed to be transitional cell cancer. The sen- sitivity of ImmunoCyt was 88.2 %, while that of cytology was 47.1%. When they were combined, the sensitivity was 91.2%. The specificity of ImmunoCyt was 80.4%, while that of cytology was 95.3%. [Conclusion] The sensitivity of ImmunoCyt is higher than that of cytology. When they are combined, the sensitivity and specificity can be improved. They are suitable for mass survey and follow-up after operation in the early diagnosis of bladder cancer with low grade and stage and less possibility.
作者 范海涛
出处 《医学临床研究》 CAS 2009年第1期37-39,共3页 Journal of Clinical Research
关键词 膀胱肿瘤/诊断 移行性细胞/诊断 bladder neoplasms/DI carcinoma,transitional cell/DI
  • 相关文献

参考文献11

  • 1Laufer M. Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder.a phase Ⅰ and pharmacokinetic study[J]. J Clin Oncol , 2003,21 (4) : 697-703.
  • 2Riehhars L, Michael JD. The natural history of bladder cancer [J]. Urol Clin North Am ,2000,27(1):1-14.
  • 3Jichlinski P. New diagnostic strategies in the detection and staging of bladder eancer[J]. Curr Opin Urol ,2003,13(5) : 351-355.
  • 4黎明,章振保,林炳森,张淳,郑俊鸿.CD147与VEGF在人膀胱移行细胞癌中的表达及其临床意义[J].医学临床研究,2007,24(4):604-606. 被引量:6
  • 5曲巍,王立明.抗肿瘤药物膀胱灌注的研究进展[J].国外医学(泌尿系统分册),2004,24(3):341-345. 被引量:13
  • 6Brown FM. Urine cytology. Is it still the gold standard for screening[J]? Urol Clin North Am , 2000,27 ( 1 ): 25-37.
  • 7Lokeshwar VB. Current bladder tumor tests: does their projected utility fulfill clinical necessity[J]? J Urol , 2001,165 (4) : 1067-1077.
  • 8Pfister C. ImmunoCyt test improves the diagnostic accuracy of urinary cytology:results of a French multicenter study[J]. J Urol ,2003,169(3) :921-924.
  • 9Fell G. Accuracy of the ImmunoCyt assay in the diagnosis of transitional cell carcinoma of the urinary bladder [J]. Anticancer Res ,2003,23(2A) :963-967.
  • 10Lodde M. Immunocyt for the detection of transitional cell cancer of the urinary tract[J]. J Urol ,1999,161(1) :150.

二级参考文献33

  • 1Laufer M,Ramalingam S,Schoenberg MP,et al.Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder:a phase I and pharmacokinetic study.J Clin Oncol,2003,21(4),697~703
  • 2Uchio EM,Linehan WM,Figg WD,et al.A phase I study of intravesical suramin for the treatment of superficial transitional cell carcinoma of the bladder.J Urol,2003,169(1),357~60
  • 3Dalbagni G,Herr HW.Current use and questions concerning intravesical bladder cancer group for superficial bladder cancer.Urol Clin North Am,2000,27(1),137~46
  • 4Kondas J,Kiss L,Hatar A,et al.The effect of intravesical mitomycin C on the recurrence of superficial(Ta-T1) bladder cancer.A Hungarian Multicenter Study.Int Urol Nephrol,1999,31(4),451~6
  • 5Solsona E,Iborra I,Ricos JV,et al.Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer:short and long-term followup.J Urol,1999,161(4),1120~3
  • 6Nomata K,Noguchi M,Kanetake H,et al.Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma:results of a randomized trial with epirubicin comparing short-term versus long-term maintenance treatment.Cancer Chemother Pharmacol,2002,50(4),266~70
  • 7Bassi P,Spinadin R,Longo F.Delayed high-dose intravesical epirubicin therapy of superficial bladder cancer.A way to reduce the side effects and increase the efficacy-a phase 2 trial.Urol Int,2002,68(4),216~9
  • 8Patterson AL,Greenberg RE,Weems L,et al.Pilot study of the tolerability and toxicity of intravesical valrubicin immediately after transurethral resection of superficial bladder cancer.Urology,2000,56(2),232~5
  • 9Newling DW,Hetherington J,Sundaram SK,et al.The use of valrubicin for the chemoresection of superficial bladder cancer-a marker lesion study.Eur Urol,2001,39(6),643~7
  • 10Chiang PH,Chiang CP.Intravesical mitoxantrone in superficial bladder cancer.Kaohsiung J Med Sci,2000,16(2),91~4

共引文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部